Market Access

Recent history should have the pharmaceutical industry questioning some of its fundamental assumptions. The COVID-19 pandemic led to

Why reshoring drug production means embracing continuous manufacturing

https://pharmaphorum.com/market-access-2/why-reshoring-drug-production-means-embracing-continuous-manufacturing/

Market Access/ News/ News/ News/ News/ Patients/ Sales and Marketing

Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld

Phil Taylor access, AstraZeneca, coronavirus, COVID-19, Evusheld, procurement, UK 0 Comment

Half a million people in the UK with conditions like blood cancer that prevents them being protected from

Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld

https://pharmaphorum.com/news/dismay-as-uk-drags-its-heels-on-azs-covid-antibody-evusheld/

Market Access/ News/ News/ News/ Oncology

Novartis’ Pluvicto gets first European approval in GB

Phil Taylor Novartis, Oncology, Pluvicto, Prostate cancer, radioligand, regulatory approval, UK 0 Comment

Novartis has secured its first approval in Europe for prostate cancer radioligand therapy Pluvicto, getting a green light

Novartis’ Pluvicto gets first European approval in GB

https://pharmaphorum.com/news/novartis-pluvicto-gets-first-european-approval-in-gb/

Market Access/ News/ News/ News/ Oncology

AZ gets FDA nod for Enhertu in first HER2-low cancer

Phil Taylor AstraZeneca, breast cancer, Enhertu, fda, her2, Oncology, regulatory approval 0 Comment

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu as the first targeted therapy for HER2-low breast cancer,

AZ gets FDA nod for Enhertu in first HER2-low cancer

https://pharmaphorum.com/news/az-gets-fda-nod-for-enhertu-in-first-her2-low-cancer/

Market Access/ News/ News

US Democrats’ blockbuster budget bill could spell big changes for drug prices

Jonah Comstock Drug pricing, Joe Biden, Medicare, PhRMA, US Senate 0 Comment

The Inflation Reduction Act of 2022, a sweeping measure that now looks likely to be passed through budget

US Democrats’ blockbuster budget bill could spell big changes for drug prices

https://pharmaphorum.com/market-access-2/us-democrats-blockbuster-budget-bill-could-spell-big-changes-for-drug-prices/

Market Access/ News/ News/ News/ Oncology

Sanofi looks east with €300m Innovent cancer alliance

Phil Taylor China, immuno-oncology, Innovent, Oncology, partnering, Sanofi, sintilimab, tusamitamab ravtansine 0 Comment

Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring

Sanofi looks east with €300m Innovent cancer alliance

https://pharmaphorum.com/news/sanofi-looks-east-with-e300m-innovent-cancer-alliance/

Market Access/ News/ News/ News/ Sales and Marketing

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

Phil Taylor biosimilar, Byooviz, Cimerli, Coherus, Lucentis, Novartis, Roche, Samsung Bioepis 0 Comment

The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

https://pharmaphorum.com/news/pressure-rises-on-lucentis-as-coherus-biosimilar-gets-fda-nod/

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Philips on designing innovation and cultivating partnerships – part two

Jessica Hagen collaboration, pharma, Philips, Philips Africa, Philips India 0 Comment

This article follows part one of our two-part series, where we discussed how Philips designs innovation and digital

Philips on designing innovation and cultivating partnerships – part two

https://pharmaphorum.com/market-access-2/philips-on-designing-innovation-and-cultivating-partnerships-part-two/

Young man in a wheelchair looking at the nature

Market Access/ News/ News

Sarepta says early filing for DMD gene therapy is back on

Phil Taylor Duchenne muscular dystrophy, gene therapy, genetic diseases, Sarepta 0 Comment

Sarepta is pressing forward with a bold plan to file with the FDA for accelerated approval of its

Sarepta says early filing for DMD gene therapy is back on

https://pharmaphorum.com/news/sarepta-says-early-filing-for-dmd-gene-therapy-is-back-on/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Market Access

Login